Sgd Pharma, headquartered in France, is a prominent player in the rubber and plastic products industry, specifically within the pharmaceutical packaging sector. Established in 1996, the company has made significant strides in providing innovative solutions for the global market, with major operational regions across Europe, Asia, and the Americas.
Specialising in the design and manufacture of high-quality glass and plastic containers, Sgd Pharma stands out for its commitment to sustainability and advanced technology. Their core offerings include vials, bottles, and closures that meet stringent regulatory standards, ensuring product safety and integrity. With a strong market position, Sgd Pharma has achieved notable milestones, including numerous certifications and awards for excellence in quality and environmental responsibility.
+3 vs industry average
Sgd Pharma’s score of 24 is lower than 48% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sgd Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Rubber and Plastic Products has above-average carbon intensity
Industry performance
The Rubber and Plastic Products industry has reduced its overall emissions by 30% since 2019
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Sgd Pharma's reported carbon emissions
SGD Pharma, a company in the rubber and plastic products industry based in France, has reported its carbon emissions and climate commitments. In 2024, SGD Pharma reported Scope 1 and 2 emissions totalling approximately 181.5 million kg CO2e (market-based). Scope 1 emissions for 2024 were approximately 121.6 million kg CO2e, and Scope 2 emissions were approximately 59.9 million kg CO2e. For 2023, the company's Scope 1 and 2 emissions were approximately 199.7 million kg CO2e (market-based). SGD Pharma has set several reduction targets. The company aims to cut Scope 1 and 2 CO2 emissions by 42% by 2030 compared to 2022 levels, aligning with a 1.5°C climate threshold. Additionally, SGD Pharma's plants in France, Germany, India, and China have a goal to reduce Scope 1 and 2 emissions by 35% by 2030 and by 65% by 2040, using a 2020 baseline. Looking further ahead, SGD Pharma is targeting a 65% reduction in CO2 emissions by 2040. The company also has a long-term goal of achieving carbon neutrality by 2050.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sgd Pharma’s Climate Goals (2030 & 2050)
6 goals2040
65% reduction in all scopes
Looking ahead, SGD Pharma is targeting a 65% reduction in CO2 emissions by 2040 and will continue to work to increase this number.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 6 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Sgd Pharma
Frequently asked questions
Common questions about Sgd Pharma’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project